Drugs / ANS02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07538804 | Jul 2026 → Jun 2029 expected | non-small cell lung carcinoma | Avistone Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANS02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07538804 ↗ |
| Route | Oral | “ANS02 capsules, oral administration” NCT07538804 ↗ |